We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




mHealth Device Identifies Heart Problems in Cancer Survivors

By HospiMedica International staff writers
Posted on 05 Jul 2018
Print article
Image: The Vivio app measuring pulse on an iPhone (Photo courtesy of Niema Pahlevan/ USC).
Image: The Vivio app measuring pulse on an iPhone (Photo courtesy of Niema Pahlevan/ USC).
A novel handheld platform can accurately detect cardiac dysfunction in childhood cancer survivors, according to a new study.

The Vivio device, developed at the California Institute of Technology (Caltech; Pasadena, USA), the University of Southern California (USC; Los Angeles, USA), and other institutions, is a handheld device that collects pulse waves and phonocardiogram data from the carotid artery and sends it wirelessly to an app on a compatible device, such as a smartphone or tablet. Using a specialized algorithm, left ventricular ejection fraction (LVEF) is calculated; an LVEF measure of less than 50% may indicate signs of abnormal heart function.

To test the accuracy of the device, researchers at the Childhood Cancer Survivorship Clinic (CCSC) at City of Hope (Duarte, CA, USA) conducted a cross-sectional study that compared LVEF using the Vivio wireless device, two-dimensional (2D) echocardiography, and gold-standard cardiac magnetic resonance (CMR) imaging in childhood cancer survivors exposed to anthracycline, who risk potential cardiac dysfunction from the exposure, which can often develop at a time when they are least engaged in long-term survivorship care.

In all, 191 consecutive cancer survivors participated in the study, with a median anthracycline dose of 225 mg/m². The researchers found that echocardiography overestimated mean LVEF by 4.9% compared with CMR, but no difference was seen between mean LVEF derived from the Vivio and CMR. Also, when compared with CMR, the detection of cardiac dysfunction via echocardiography was poor, but Vivio-based measurements had considerably better sensitivity. The study was published on June 21, 2018, in Clinical Cancer Research.

“The pediatric oncology community is becoming increasingly aware that there are new issues faced by many cancer survivors that may not manifest themselves until decades after their cancer treatment is done,” said lead author pediatric hematologist/oncologist Saro Armenian, DO, MPH, director of the CCSC. “One of these issues is a higher burden of cardiovascular disease, which can result from exposure to anthracyclines as part of their cancer treatment.”

“One possible implementation of Vivio could be for preliminary screening. If the patient's heart function is below a specific threshold as measured by Vivio, that patient could schedule an in-depth evaluation,” concluded Dr. Armenian. “Vivio could keep these survivors engaged, and help to reduce the burden of inconvenient tests for individuals with a normal heart function as determined by the device. It could also pave the way for a mobile health-based care management program for childhood cancer survivors.”

LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart with each contraction, and is usually expressed as a percentage. A normal LVEF ranges from 55-70%. An LVEF of less than 40% may confirm a diagnosis of heart failure. An LVEF of less than 35% increases the risk of an arrhythmia that can cause sudden cardiac arrest or death, and an ICD may be recommended for these patients.

Related Links:
California Institute of Technology
University of Southern California
City of Hope

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Single Cavity Combination Warmer
EC550BL

Print article

Channels

Surgical Techniques

view channel
Image: The Early Bird Bleed Monitoring System provides visual and audible indicators of the onset and progression of bleeding events (Photo courtesy of Saranas)

Novel Technology Monitors and Lowers Bleeding Complications in Patients Undergoing Heart Procedures

Bleeding complications at the femoral access site can significantly hamper recovery, affecting the success of procedures, patient satisfaction, and overall healthcare costs. It is crucial for surgeons... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.